インシリコ臨床試験市場：治療領域、フェーズ、産業別-2025-2030年の世界予測

インシリコ臨床試験市場の2023年の市場規模は30億1,000万米ドル、2024年には31億9,000万米ドルに達すると予測され、CAGR 7.01％で成長し、2030年には48億5,000万米ドルに達すると予測されています。

インシリコ臨床試験は、新薬や新装置の安全性と有効性を予測するために使用されるコンピュータシミュレーション解析と定義され、大幅な成長が見込まれる急成長分野です。これらの臨床試験は、in vivoやin vitroの手法に代わる、あるいはそれを補完するものであり、従来の臨床試験に内在する時間、コスト、倫理的な懸念を大幅に軽減するものです。その用途は、創薬・薬剤開発から個別化医療まで多岐にわたり、企業は、現実には実施不可能あるいは不可能な無数のシナリオをシミュレートすることができます。主なエンドユーザーには、製薬会社、ヘルスケアプロバイダー、研究機関、規制当局などが含まれ、これらすべてが予測能力の強化と規制審査の迅速化から利益を得ています。市場開拓は、計算モデリングの進歩、医薬品開発におけるコスト削減の必要性の高まり、個別化医療に対する需要の高まりなどの要因によって促進されます。人工知能や機械学習のような新技術に潜在的な機会があり、予測精度とプロセス効率をさらに高めることができます。しかし、標準化が不十分であること、高品質なデータが必要であること、規制上のハードルが高いことなどの制約が、導入の課題となっています。利害関係者は、拡大する動向を十分に活用するために、これらの問題に焦点を当てることが極めて重要です。技術革新が必要な分野には、データ統合手法の改善、強固な規制枠組みの開発、より広範な採用を促進するユーザーフレンドリーなプラットフォームの構築などがあります。急速な技術の進歩と規制の進化を特徴とする市場のダイナミックな性質を考慮すると、プレーヤーは戦略的パートナーシップと継続的な研究開発投資を優先し、競争力を維持すべきです。さらに、これらの技術がより信頼され、制度的に支持されるようになれば、既存の医薬品を再利用し、新たな治療経路を特定する変革的な可能性を秘め、それによって臨床研究の展望を再形成し、従来の枠を超えたビジネスの成長を促進することになります。

市場力学：急速に進化するインシリコ臨床試験市場の主要市場インサイトを公開

インシリコ臨床試験市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の慢性疾患の流行と効率的な医薬品へのニーズの高まり
  • 医薬品や医療機器の安全性と有効性をより深く理解する必要性の高まり
  • 医薬品開発のための研究開発費の大幅な増加
• 市場抑制要因
  • 新興経済諸国におけるインシリコ試験に対する認知度の低さ
• 市場機会
  • インシリコ臨床試験における技術の進歩
  • 高度な計算モデリングおよびシミュレーションツールの利用
• 市場の課題
  • タンパク質の柔軟性、分子のコンフォメーション、乱雑性に関する問題

ポーターのファイブフォースインシリコ臨床試験市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：インシリコ臨床試験市場における外部からの影響の把握

外部マクロ環境要因は、インシリコ臨床試験市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析インシリコ臨床試験市場における競合情勢の把握

インシリコ臨床試験市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスインシリコ臨床試験市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、インシリコ臨床試験市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨インシリコ臨床試験市場における成功への道筋を描く

インシリコ臨床試験市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で慢性疾患の罹患率が上昇し、効果的な薬の必要性が高まっている
    • 医薬品や医療機器の安全性と有効性をより深く理解する必要性が高まっている
    • 医薬品開発のための研究開発費の大幅な増加
  • 抑制要因
    • 新興経済諸国におけるin silico試験に関する認知度の低さ
  • 機会
    • インシリコ臨床試験における技術的進歩
    • 高度な計算モデリングおよびシミュレーションツールの活用
  • 課題
    • タンパク質の柔軟性、分子の立体配座、および乱交性に関する問題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 インシリコ臨床試験市場治療領域別

• 感染症
• 腫瘍学

第7章 インシリコ臨床試験市場フェーズ別

• フェーズI
• フェーズII
• フェーズIII

第8章 インシリコ臨床試験市場：業界別

• 医療機器
• 製薬

第9章 南北アメリカのインシリコ臨床試験市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のインシリコ臨床試験市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのインシリコ臨床試験市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Aganitha AI Inc.
• GNS Healthcare
• Insilico Medicine
• InSilicoTrials Technologies
• Instem Group of Companies
• Labcorp Drug Development
• Novadiscovery SAS
• Thornton Tomasetti
• ZMT Zurich MedTech AG

LIST OF FIGURES

• FIGURE 1. IN SILICO CLINICAL TRIALS MARKET RESEARCH PROCESS
• FIGURE 2. IN SILICO CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. IN SILICO CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. IN SILICO CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IN SILICO CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IN SILICO CLINICAL TRIALS MARKET DYNAMICS
• TABLE 7. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 27. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 28. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 44. CHINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 45. CHINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 47. INDIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 48. INDIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 99. ITALY IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 100. ITALY IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 111. POLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 112. POLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 114. QATAR IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 115. QATAR IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
• TABLE 144. IN SILICO CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 145. IN SILICO CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

The In Silico Clinical Trials Market was valued at USD 3.01 billion in 2023, expected to reach USD 3.19 billion in 2024, and is projected to grow at a CAGR of 7.01%, to USD 4.85 billion by 2030.

In silico clinical trials, defined as computer-simulated analyses used to predict the safety and efficacy of new drugs and devices, represent a burgeoning field poised for substantial growth. These trials provide a necessary alternative or complement to in vivo and in vitro methods, significantly reducing time, cost, and ethical concerns inherent in traditional clinical trials. Their application spans a wide array of uses, from drug discovery and development to personalized medicine, allowing companies to simulate myriad scenarios that might be impractical or impossible to conduct in real life. Key end-users include pharmaceutical companies, healthcare providers, research institutions, and regulatory agencies, all of which benefit from enhanced prediction capabilities and expedited regulatory reviews. Market growth is fueled by factors such as advances in computational modeling, the increasing necessity for cost reduction in drug development, and heightened demand for personalized medicine. Potential opportunities lie in emerging technologies like artificial intelligence and machine learning, which can further enhance predictive accuracy and process efficiency. However, adoption is challenged by limitations such as inadequate standardization, the necessity of high-quality data, and regulatory hurdles. It is crucial for stakeholders to focus on these issues to fully capitalize on the growing trend. Areas ripe for innovation include improving data integration methods, developing robust regulatory frameworks, and creating user-friendly platforms that facilitate broader adoption. Given the market's dynamic nature, characterized by rapid technological advancements and regulatory evolution, players should prioritize strategic partnerships and continuous R&D investment to stay competitive. Moreover, as these technologies become more trusted and institutionally supported, they hold the transformative potential to repurpose existing drugs and identify new therapeutic pathways, thereby reshaping the landscape of clinical research and facilitating business growth beyond conventional boundaries.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In Silico Clinical Trials Market

The In Silico Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of chronic diseases worldwide and need for efficient drugs
  • Growing need for better understanding of the safety and efficacy of a drug or a device
  • Significant rise in R&D expenditure for drug development
• Market Restraints
  • Low awareness about in silico trials in the developing economies
• Market Opportunities
  • Technological advancements in in silico clinical trials
  • Utilization of use advanced computational modeling and simulation tools
• Market Challenges
  • Issues related to protein flexibility, molecule conformation, and promiscuity

Porter's Five Forces: A Strategic Tool for Navigating the In Silico Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In Silico Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In Silico Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In Silico Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In Silico Clinical Trials Market

A detailed market share analysis in the In Silico Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In Silico Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In Silico Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In Silico Clinical Trials Market

A strategic analysis of the In Silico Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In Silico Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include Aganitha AI Inc., GNS Healthcare, Insilico Medicine, InSilicoTrials Technologies, Instem Group of Companies, Labcorp Drug Development, Novadiscovery SAS, Thornton Tomasetti, and ZMT Zurich MedTech AG.

Market Segmentation & Coverage

This research report categorizes the In Silico Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapeutic Area, market is studied across Infectious Diseases and Oncology.
• Based on Phase, market is studied across Phase I, Phase II, and Phase III.
• Based on Industry, market is studied across Medical Devices and Pharmaceutical.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic diseases worldwide and need for efficient drugs
    • 5.1.1.2. Growing need for better understanding of the safety and efficacy of a drug or a device
    • 5.1.1.3. Significant rise in R&D expenditure for drug development
  • 5.1.2. Restraints
    • 5.1.2.1. Low awareness about in silico trials in the developing economies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in in silico clinical trials
    • 5.1.3.2. Utilization of use advanced computational modeling and simulation tools
  • 5.1.4. Challenges
    • 5.1.4.1. Issues related to protein flexibility, molecule conformation, and promiscuity
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. In Silico Clinical Trials Market, by Therapeutic Area

• 6.1. Introduction
• 6.2. Infectious Diseases
• 6.3. Oncology

7. In Silico Clinical Trials Market, by Phase

• 7.1. Introduction
• 7.2. Phase I
• 7.3. Phase II
• 7.4. Phase III

8. In Silico Clinical Trials Market, by Industry

• 8.1. Introduction
• 8.2. Medical Devices
• 8.3. Pharmaceutical

9. Americas In Silico Clinical Trials Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific In Silico Clinical Trials Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa In Silico Clinical Trials Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aganitha AI Inc.
• 2. GNS Healthcare
• 3. Insilico Medicine
• 4. InSilicoTrials Technologies
• 5. Instem Group of Companies
• 6. Labcorp Drug Development
• 7. Novadiscovery SAS
• 8. Thornton Tomasetti
• 9. ZMT Zurich MedTech AG